CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
brivaracetamdrug
Likely dose
brivaracetam 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04882540
NCT04882540Phase 1Completed
CompareCT.gov

An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of a Single and Multiple Oral Doses of Brivaracetam in Healthy Adult Chinese Subjects

UCB Biopharma SRL·interventional·Posted May 12, 2021·Updated Mar 13, 2023

In Brief

A Phase 1 clinical trial evaluating brivaracetam for Healthy Participants. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of the study is to assess the pharmacokinetics, safety, and tolerability of brivaracetam after a single dose and multiple doses in healthy adult Chinese Study Participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedMay 12, 2021
Enrollment StartMay 19, 2021
Primary CompletionJun 8, 2021
TodayJul 2, 2026
Enrollment to primary: 19 daysPosted 5.1 years ago

Interventions

brivaracetamdrug

* Pharmaceutical form: Film-coated tablets * Concentration: 100 mg tablets * Route of administration: Oral use